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A decade since the ﬁrst evidence implicating the cell cycle transcription factor Forkhead
Box M1 (FOXM1) in human tumorigenesis, a slew of subsequent studies revealed an
oncogenic role of FOXM1 in the majority of human cancers including oral, nasopharynx,
oropharynx, esophagus, breast, ovary, prostate, lung, liver, pancreas, kidney, colon, brain,
cervix, thyroid, bladder, uterus, testis, stomach, skin, and blood. Its aberrant upregulation in
almost all different cancer types suggests a fundamental role for FOXM1 in tumorigenesis.
Its dose-dependent expression pattern correlatedwell with tumor progression starting from
cancer predisposition and initiation, early premalignancy and progression, to metastatic
invasion. In addition, emerging studies have demonstrated a causal link between FOXM1
and chemotherapeutic drug resistance. Despite the well-established multifaceted roles for
FOXM1 in all stages of oncogenesis, its translation into clinical beneﬁt is yet to materialize.
In this contribution, I reviewed and discussed how our current knowledge on the oncogenic
mechanisms of FOXM1 could be exploited for clinical use as biomarker for risk prediction,
early cancer screening, molecular diagnostics/prognostics, and/or companion diagnostics
for personalized cancer therapy.
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INTRODUCTION
The human Forkhead Box M1 (FOXM1) protein, belongs to a
winged-helix transcription factor family (Jackson et al., 2010), was
ﬁrst identiﬁed as a mitotic-phase phosphoprotein (MPP2) from
a cervical cancer HeLa cell line (Westendorf et al., 1994) and its
gene structure later mapped to chromosome 12p13.3 consisting
of 10 exons, two of which are alternatively expressed thereby pro-
ducing three alternatively spliced mRNA isoforms (Korver et al.,
1997; Ye et al., 1997). Although all three protein isoforms of
FOXM1 can bind to DNA, only FOXM1B and FOXM1C (iso-
form 2) were shown to be transcriptionally active (Korver et al.,
1997; Ye et al., 1997). FOXM1A was found to be transcriptionally
inactive due to the presence of an inhibitory exon (A2) in the C-
terminal of its transactivation domain (Ye et al., 1997). Although
FOXM1B was found to be the only isoform showing cell cycle-
dependent mRNA expression in two different human cell lines
(Gemenetzidis et al., 2010), it was not clear if this was due to
splicing variations or other mechanisms, hence, further studies
are required to clarify this issue. Most studies to date focused on
FOXM1B and FOXM1C due to their transactivating roles in cell
cycle which inadvertently led to the lack of studies on the inactive
isoform FOXM1A whereby its role in cell cycle remains unknown.
Given the presence of three FOXM1 isoforms in human, two in
rat and one in mouse, the functional signiﬁcance and interac-
tions amongst the three human FOXM1 isoforms deserves further
investigations.
FOXM1 IN HUMAN CANCER
Early studies have demonstrated that FOXM1 was upregulated
in a variety of human epithelial cancer cell lines (Ye et al., 1997)
and that the high risk human papillomavirus (HPV) type 16 E7
oncoprotein interacted with Foxm1 to promote malignant trans-
formation in cultured rat embryo ﬁbroblasts (Luscher-Firzlaff
et al., 1999). However, it was not clear whether FOXM1 had a
causative role in human cancer in vivo until the ﬁrst evidence
demonstrated that FOXM1 was upregulated in basal cell carci-
nomas (Teh et al., 2002), one of the most common human skin
cancers worldwide. FOXM1 was a downstream target of an onco-
genic Sonic Hedgehog signaling pathway via a glioma family zinc
ﬁnger transcription factor 1 (Gli1) in basal cell carcinomas (Teh
et al., 2002). Subsequent studies revealed that FOXM1 was aber-
rantly upregulated in the majority of human cancers (Myatt and
Lam, 2007; Wierstra and Alves, 2007) which include liver, breast,
prostate, lung, brain, colon, pancreas, testis, bladder, kidney,
ovary, uterus, cervix, oral (Gemenetzidis et al., 2009;Waseem et al.,
2010), stomach (Li et al., 2009), blood (acute myeloid leukemia;
Nakamura et al., 2010), cutaneousmelanoma (Huynh et al., 2011),
thyroid carcinoma (Ahmed et al., 2012), nasopharyngeal carci-
noma (Chen et al., 2012), and esophageal cancer (Gemenetzidis
et al., 2009; Hui et al., 2012).
Given a role in cell cycle, it is not surprising that FOXM1
plays a pivotal role in tumorigenesis. FOXM1 expression level
has been shown in numerous types of human cancer to be
dose-dependently correlated with tumor progression starting
from cancer predisposition and initiation (Gemenetzidis et al.,
2010; Jia et al., 2010; Teh et al., 2010), early premalignancy and
progression (Gemenetzidis et al., 2009; Nakamura et al., 2010;
Waseem et al., 2010; Huynh et al., 2011) to metastatic invasion
(reviewed in Wierstra and Alves, 2007). Importantly, FOXM1
expression has been inversely correlated with poor prognosis
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in patients with oral squamous cell carcinoma (Chen et al.,
2009), glioblastoma (Liu et al., 2006), breast cancer (Bektas et al.,
2008; Martin et al., 2008), hepatocellular carcinoma (Sun et al.,
2011; Xia et al., 2012), pulmonary squamous cell carcinoma
(Yang et al., 2009), and colorectal cancer (Chu et al., 2012). Fur-
thermore, emerging studies have shown that FOXM1 confers
resistance to a wide variety of breast cancer chemotherapeutic
drugs (reviewed in Wilson et al., 2011). Hence, it appears that
FOXM1 is required andnecessary in all stages of tumorigenesis and
metastasis.
FOXM1 IN STEM CELL FATE DETERMINATION AND
CANCER INITIATION
Adult stem cells are responsible for tissue homeostasis and repair.
However, due to their inherently high clonogenic potential and
plasticity, stem cells are susceptible to oncogenic selection ren-
dering these cells ideal targets for cancer initiation. In rare
occasions, tumors may arise spontaneously and rapidly with-
out sequential accumulation/selection of oncogenic mutations
through a catastrophic genomic rearrangement event, namely
chromothripsis (Liu et al., 2011; Stephens et al., 2011; Crasta
et al., 2012). Nevertheless, it is generally accepted that the major-
ity of malignancies are initiated by stem cells which accumulate
and propagate oncogenic mutations through clonal evolutionary
selection.
Emerging evidence have indicated that FOXM1plays an impor-
tant role in maintaining stem cell renewal through pluripotency
genes Oct4, Nanog, and Sox2 in mouse (Xie et al., 2010; Tomp-
kins et al., 2011; Wang et al., 2011). A recent mouse model study
established a key role for FOXM1 in cell fate determination. This
study showed that FOXM1 regulated mammary luminal cell fate
by modulating the expression of GATA-3, a key regulator of
breast luminal epithelial differentiation (Carr et al., 2012). Fur-
thermore, FOXM1 has been shown to transactivate an epithelial
stem cell marker keratin 15 (KRT15) gene in human keratinocytes
(Bose et al., 2012).
It has been demonstrated that environmental (e.g., sun expo-
sure) and carcinogenic factors (e.g., tobacco use, etc.) can cause
aberrant expressionof FOXM1 leading to cellular proliferation and
promote oncogenic genomic instability in human cells (Figure 1).
It has been shown that ionizing radiation, etoposide, or ultravio-
let light-induced DNA damage leads to Chk2-mediated FOXM1
phosphorylation and its stabilization (Tan et al., 2007). Further-
more, repeated ultraviolet B irradiation on human keratinocytes
enhanced FOXM1-associated genomic instability in the form
of loss of heterozygosity (LOH) and copy number aberrations
(CNA) perturbing genomic loci containing large number of genes,
for example, epidermal growth factor receptor (EGFR), insulin-
like growth factor 2 receptor (IGF2R), and insulin-like growth
factor binding protein 1/3 (IGFBP1/3), which have been previ-
ously linked to oncogenesis of human squamous cell carcinoma
(Teh et al., 2010). Similarly, nicotine has been shown to pro-
mote malignant transformation by enhancing FOXM1-associated
LOH and CNA, whereby malignant cells bearing ampliﬁed CNV
loci (10q23) containing a centrosomal protein CEP55 respon-
sible for cytokinesis and a chromatin-remodeling helicase/stem
cell factor HELLS known to regulate epigenetic reprograming
(Gemenetzidis et al., 2009; Teh et al., 2012). The complexity of
genomic instability and epigenetic reprograming activated by
FOXM1 may therefore generate a highly heterogeneous popula-
tion of mutant cells ready to adopt subsequent oncogenic insults
whichmay explain the heterogeneity exists inmany cancers. Taken
together, these studies support a driver role of FOXM1 in can-
cer predisposition and initiation through perturbation of the
genomic and epigenomic landscapes (Gemenetzidis et al., 2009;
Teh et al., 2010, 2012).
It was unclear how normal healthy cells retain abnormal
expression of FOXM1 following exposure to carcinogens. Using
a well-established three dimension (3D) human organotypical
tissue culture model system enabled us to study epithelial differ-
entiation and renewal mechanism with high degree of similarity
to human tissue regeneration in vivo (Gemenetzidis et al., 2010)
without provoking ethical issues associated with human or animal
subjects. This humanorganotypical culture study has provided the
ﬁrst direct evidence that FOXM1 regulates human adult epithe-
lial stem cell fate (Gemenetzidis et al., 2010). Overexpression of
FOXM1 in human keratinocyte stem/progenitor cells, but not
in differentiating cells, signiﬁcantly expanded the proliferative
progenitor compartment by perturbing epithelial differentiation
producing a hyperproliferative phenotype reminiscent of that seen
in hyperplasia – a condition that carries a risk of malignant
transformation depending on subsequent oncogenic hits. This
ﬁnding indicates that FOXM1 hijacks the self-renewal proper-
ties of stem cells to initiate a premalignant condition sustained
by molecularly distinct “pre-cancer” stem cells. The acquisition of
aberrant expression of FOXM1by normal stem cellsmay represent
a key driver step in a multistep oncogenic evolutionary pathway
(Figure 1).
Ectopic FOXM1 has been found to induce stem/progenitor
compartment expansion by shifting the balance toward stem
cell renewal whilst perturbing differentiation (Gemenetzidis et al.,
2010; Bao et al., 2011; Kalin et al., 2011; Wang et al., 2011;
Bose et al., 2012) and cause genomic instability in human cells
through deregulation of mitosis and/or cytokinesis (Laoukili et al.,
2005; Gemenetzidis et al., 2009). Moreover, aberrant FOXM1
expression also induces epigenomic perturbations through activa-
tion of a chromatin-remodeling helicase/stem cell factor HELLS
(Gemenetzidis et al., 2009; Teh et al., 2012), activated epithelial–
mesenchymal transition (reviewed in Wierstra and Alves, 2007;
Gemenetzidis et al., 2010; Kalin et al., 2011) and induces DNA-
repair/drug resistance pathways (reviewed in Wilson et al., 2011).
Collectively, these ﬁndings illustrate diverse molecular mecha-
nisms of how aberrant expression of FOXM1 may play pivotal
roles in all stages of tumorigenesis from initiation to metastatic
invasion.
CLINICAL TRANSLATION
Understanding the basic molecular mechanism of FOXM1-
driven oncogenesis is prerequisite to exploitation for clinical
beneﬁts. Given that FOXM1 has been implicated in all stages
from cancer initiation, progression, metastasis to drug resis-
tance, FOXM1 is evidently a promising cancer biomarker. How-
ever, understanding the detail molecular mechanisms speciﬁc to
each disease stages would be important to reveal stage-speciﬁc
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FIGURE 1 | A model mechanism illustrating the role of FOXM1 in human
epithelial cancer initiation, progression, and metastasis. Multiple lines of
evidence have suggested that carcinogens (such as ultraviolet light, ionizing
radiation, tobacco, etc) exposure causes activation of FOXM1 which triggers
aberrant expansion of “pre-cancer stem cells” through perturbation of
epithelial differentiation, producing a premalignant hyperplastic phenotype
(Gemenetzidis et al., 2010). Activation of genomic instability (e.g., through
activation of CEP55 leading to mitotic instability; Gemenetzidis et al., 2009)
and epigenetic reprograming (e.g., through deregulation of HELLS causing
chromatin remodeling and altered genomic methylation) triggered by aberrant
expression of FOXM1 (Teh et al., 2012) may predispose cells to further
mutations thereby driving oncogenic progression and subsequent metastatic
invasion. Due to the complexity of genomic instability and epigenetic
reprograming activated by FOXM1, this model may explain the heterogeneity
found in tumor whereby the initial molecularly distinct “pre-cancer stem
cells” undergo constant adaptive evolutionary changes to produce “cancer
stem cells” and subsequently “metastatic cancer stem cells” during the
course of cancer progression. An alternative mechanism involving
catastrophic genomic rearrangement, chromothripsis, has been shown to
produce tumor directly and rapidly from normal cells without the need for
sequential accumulation of oncogenic mutations (Liu et al., 2011; Stephens
et al., 2011; Crasta et al., 2012).
FOXM1-associated biomarker panels as illustrated in Figure 2.
Furthermore, identiﬁcation of such stage-speciﬁc biomarkers
could in turn stimulate further research into ﬁnding new anti-
tumor drugs with better speciﬁcity and efﬁcacy.
EPIGENETIC ALTERATIONS AS PREDICTIVE CANCER
BIOMARKERS
Epigenetic programing plays a key role in cell fate diversiﬁcation
that involves mechanisms such as stem cell renewal, prolifera-
tion, differentiation, and aging (Baylin and Jones, 2011). DNA
methylation is one of the fundamental epigenetic programing
mechanisms whereby its heritable yet reversible methylome land-
scapes is able to produce diverse phenotypes from a single genome
without altering its primary DNA sequence. Aberrant distur-
bance of the methylome landscape in normal cells is known to
induce cancer formation (Tsai and Baylin, 2011). Given a pre-
sumed higher hierarchy of the epigenome over the transcriptome
and proteome in terms of the Central Dogma of Molecular Biol-
ogy, understanding aberrant epigenetic alteration involving DNA
methylation is prerequisite to ﬁnding predictive, and/or early can-
cer biomarkers. Advances in detecting cell-free nucleic acids in
cancer patients’ blood demand better nucleic acid-based biomark-
ers (Schwarzenbach et al., 2011a). The chemically distinctive and
reversible properties of methylated DNA provide ample opportu-
nities for clinical exploitation as nucleic acid-based biomarkers
potentially detectable in non-invasive samples such as blood,
buccal scrapes, or even saliva.
Given that FOXM1 was found to “brainwash” normal cells by
reprograming the methylome and changing its landscape toward
those found in cancer cells (Teh et al., 2012), the global epige-
nomic perturbations orchestrated by FOXM1 during pre-cancer
initiation may therefore contain clinically exploitable predictive
cancer biomarkers. In the attempt to identify pre-cancer or predic-
tive cancer biomarkers accrued during aberrant cell proliferation
induced by FOXM1, we have investigated this using genome-wide
methylome arrays to identify FOXM1-orchestrated differentially
methylated genes in primary normal human epithelial cells (Teh
et al., 2012). A number of FOXM1-induced differentially methy-
lated genes were identiﬁed, including SPCS1, FLNA, CHPF,
GLT8D1, C6orf136, MGAT1, NDUFA10, and PAFAH1B3. These
genes were also found to be differentially expressed in head and
neck squamous carcinoma tumor samples compared to control
normal tissues (Teh et al., 2012). However, in order to estab-
lish whether methylation proﬁles of these genes have any cancer
predictive value, further longitudinal studies correlating pre-
symptomatic patient data with subsequent disease outcome are
required. Suchpredictive biomarkerswouldhave tremendous clin-
ical value for population screening to identify individuals with
cancer predisposition or at risk of developing cancer. Increase
public awareness, clinical surveillance and appropriate preventive
interventions, such as behavioral or lifestyle changes, may sig-
niﬁcantly delay or even avert cancer initiation. In cases where
cancer initiation could not be prevented, early detection of
pre-cancerous lesions together with appropriate intervention can
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FIGURE 2 | Strategy for translating basic FOXM1 research into clinical
benefits. FOXM1 has been implicated in all stages from cancer initiation,
progression, metastasis to drug resistance. Understanding the detail
molecular mechanisms speciﬁc to each disease stages would be important
to reveal stage-speciﬁc FOXM1-associated biomarker panels as illustrated in
the diagram. Identiﬁcation of these new stage-speciﬁc biomarkers paves
way toward further research into developing more accurate cancer
diagnosis/prognosis and better anti-tumor drugs.
signiﬁcantly improve patient’s quality of life, better treatment
outcome and alleviate healthcare costs (Baron et al., 2010). For
example, 5-year-survival rates of patients with head and neck can-
cer could be signiﬁcantly improved from less than 20% to over
80% if patients were diagnosed and treated at early cancer stages
(Haddad and Shin, 2008).
FOXM1 TRANSCRIPTIONAL TARGETS AS DIAGNOSTIC AND
PROGNOSTIC CANCER BIOMARKERS
Perturbed epigenome invariably leads to genomic instability
(Baylin and Jones, 2011; Tsai and Baylin, 2011). Aberrant expres-
sion of FOXM1 has been shown to perturb both the human
methylome (Teh et al., 2012) and induces genomic instability
(Gemenetzidis et al., 2009; Teh et al., 2010). We have found that
FOXM1-induced genomic instability leads to heritable genomic
alterations which were potentially oncogenic (Gemenetzidis et al.,
2009; Teh et al., 2010, 2012). As genomic instability precedes
malignant conversion (Gemenetzidis et al., 2009; Teh et al., 2010;
Baylin and Jones, 2011; Tsai and Baylin, 2011), these genomic
alterations are thought to contain clinically relevant “cancer
progression” biomarkers for diagnosis and prognosis. FOXM1-
induced LOH, CNA, and/or resultant gene expression alterations
may be exploited to determine disease aggressiveness or segre-
gate between high and low risks patients. For example, LOH
markers within cell-free DNA found in blood samples have been
shown to be clinically valuable as diagnostic/prognostic markers
in breast cancer patients (Schwarzenbach et al., 2011b). Extra-
cellular RNA molecules released into the blood stream were
surprisingly stable possibly protected by being packaged in exo-
somes. Emerging evidences have shown that the levels of speciﬁc
cell-free mRNA in blood samples were exploitable for clinical use
as prognostic biomarkers (Schwarzenbach et al., 2011a; Tzimagior-
gis et al., 2011). Detection of target mRNA signatures in cell-free
bioﬂuids (such as blood, urine, saliva, etc.) may therefore repre-
sent a promising non-invasive method for cancer diagnosis and
prognosis.
FUTURE PERSPECTIVE
Pre-cancer initiation and multifaceted oncogenic roles of FOXM1
in myriad of human cancers (Myatt and Lam, 2007; Koo et al.,
2012) render it a highly promising cancer biomarker for clini-
cal exploitation. Recent advances have shown promising clinical
use of multi-gene mRNA expression signature in tumor tissue
samples for cancer risk stratiﬁcation in patients with non-small
cell lung cancer (Kratz et al., 2012), prostate (Cuzick et al., 2011),
breast cancer (Kim and Paik, 2010), sarcomas, gastrointestinal
stromal tumors, and lymphomas (Chibon et al., 2010). Hence,
exploiting FOXM1 and its key oncogenic epigenetic and tran-
scriptional targets as multi-gene panels would be superior over
using a single biomarker for a complex disease such as cancer.
Disease stage-speciﬁc cancer predictive, diagnostic, and prog-
nostic biomarkers driven by FOXM1 require further discovery
and validation studies on clinical specimens. Given the role of
FOXM1 in mediating therapeutic drug resistance in cancer cells
(Koo et al., 2012), FOXM1 pathway-basedmulti-biomarkers panel
could be exploited for use as a personalized companion diag-
nostic tool to guide the best treatment strategy and improve
drug treatment response. In summary, our scientiﬁc knowledge
of FOXM1-driven oncogenesis presents multifaceted clinically
exploitable opportunities ranging from cancer prevention, early
diagnostics, and prognostics to personalized diagnostics and
therapeutics.
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